ANI Pharmaceuticals saw its stock rise following successful Phase 4 clinical trial results for an implant improving vision in a chronic eye condition. Despite the positive news, insiders including the Senior VP and CFO sold shares recently after the stock price increased. The company plans to present full trial results at a future medical meeting. ANI Pharmaceuticals currently trades around $80.55 per share with a market cap of $1.83 billion.
An attacker spent about 2 ETH to gain control of Term Finance's governance and stole $8.5 million by draining ETH and USDC from multiple strategy vaults. The attacker used Tornado Cash funds and exploited weaknesses in the voting system, not the smar...
Shein plans to raise $1.77 billion in its initial public offering (IPO) in Hong Kong by selling around 280 million shares priced between HK$47.60 and HK$49.50. The final share price will be announced on August 31, with trading expected to begin on Se...
The DRAM memory market is expected to remain tight through 2027 and beyond, benefiting Micron due to its 76% focus on DRAM products. Rapid growth in the High Bandwidth Memory (HBM) segment, where Micron holds a significant market share, is a key driv...
Lennox International reported weaker-than-expected Q2 2026 results and lowered its full-year forecast, citing softness in the residential market. Following this, its shares dropped nearly 21% in one day. Shareholders who suffered losses are being inv...
Schall, Brown & Schwartz LLP is investigating Altria Group for potentially issuing false or misleading statements and failing to disclose important information to investors. This follows Altria's Q2 2026 financial results announcement on July 30, 202...
